...
首页> 外文期刊>Nature reviews Drug discovery >Unleashing the therapeutic potential of human kallikrein-related serine proteases
【24h】

Unleashing the therapeutic potential of human kallikrein-related serine proteases

机译:释放人激肽释放酶相关丝氨酸蛋白酶的治疗潜力

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Tissue kallikreins are a family of fifteen secreted serine proteases encoded by the largest protease gene cluster in the human genome. In the past decade, substantial progress has been made in characterizing the natural substrates, endogenous inhibitors and in vivo functions of kallikreins, and studies have delineated important pathophysiological roles for these proteases in a variety of tissues. Thus, kallikreins are now considered attractive targets for the development of novel therapeutics for airway, cardiovascular, tooth, brain, skin and neoplastic diseases. In this Review, we discuss recent advances in our understanding of the physiological functions and pathological implications of kallikrein proteases, and highlight progress in the identification of kallikrein inhibitors, which together are bringing us closer to therapeutically targeting kallikreins in selected disease settings.
机译:组织激肽释放酶是由人类基因组中最大的蛋白酶基因簇编码的十五种分泌的丝氨酸蛋白酶家族。在过去的十年中,激肽释放酶的天然底物,内源性抑制剂和体内功能的表征已取得实质性进展,并且研究已经描述了这些蛋白酶在各种组织中的重要病理生理作用。因此,激肽释放酶现在被认为是开发用于气道,心血管,牙齿,大脑,皮肤和赘生性疾病的新型疗法的有吸引力的靶标。在这篇综述中,我们讨论了对激肽释放酶蛋白酶的生理功能和病理意义的理解方面的最新进展,并着重指出了激肽释放酶抑制剂的鉴定进展,这使我们在选定的疾病环境中更加接近于靶向激肽释放酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号